Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
INKTthis companyMiNK Therapeutics, Inc.	$10.48	-3.81×	-3.35×	0×	-3.2×	-89.5%	0.0%	0.0%	0.0%	87.8%	-195.5%	-12.4%	-0.36×	0.66×	0×	1.06×	0.0%	2	-26.18	2	C
CRVOCervoMed Inc.	$1.40	-2.65×	3.92×	0×	-2.34×	-51.0%	0.0%	0.0%	0.0%	-148.0%	-151.0%	-32.8%	0×	0.31×	0×	4.84×	0.0%	2	-3.92	2	C
EQEquillium, Inc.	$1.54	-3.97×	4.98×	0×	-5.06×	-77.1%	0.0%	0.0%	0.0%	-78.3%	-83.3%	-16.0%	0.03×	1.33×	0×	10.32×	0.0%	1	14.51	2	C
GANXGain Therapeutics, Inc.	$1.09	-5.28×	5.72×	0×	-4.48×	-46.1%	0.0%	0.0%	0.0%	-108.6%	-95.0%	-17.4%	0.04×	1.05×	0×	6.63×	0.0%	3	-6.34	2	C
HOWLWerewolf Therapeutics, Inc.	$1.04	-0.48×	1.18×	0×	0.36×	-2.6%	0.0%	0.0%	0.0%	-245.2%	-173.4%	-206.8%	0.38×	0.9×	-11.5×	1.62×	0.0%	4	-26.12	2	C+
NRXPNRx Pharmaceuticals, Inc.	$2.38	-2.02×	-3.64×	47.35×	-1.83×	-67.8%	58.8%	-1324.4%	-2336.5%	179.6%	106.0%	-24.3%	-0.04×	0.26×	-24.18×	0.31×	0.0%	4	-13.9	2	C+
Peer median	—	-2.65×	3.92×	0×	-2.34×	-51.0%	0.0%	0.0%	0.0%	-108.6%	-95.0%	-24.3%	0.03×	0.9×	0×	4.84×	0.0%	3	-6.34	2	—